-
Crisaborole
API’s Name Indication Innovator Patent Expiry Date(The U.S) Crisaborole Atopic Dermatitis And Eczema Pfizer -
Etelcacetide
API’s Name Indication Innovator Patent Expiry Date(The U.S) Etelcacetide Secondary hyperparathyroidism(HPT) Amgen -
Abemaciclib
API’s Name Indication Innovator Patent Expiry Date(The U.S) Abemaciclib Breast cancer, prostate cancer treatment Eli Lily Dec.15,2029 -
Deucracitinib
API’s Name Indication Innovator Patent Expiry Date(The U.S) Deucracitinib Anti plaque psoriasis Bristol-Myers Squibb Company Nov.07,2033 -
Apremilast
API’s Name Indication Innovator Patent Expiry Date(The U.S) Apremilast psoriatic arthritis Celgene -
Remdesivir
API’s Name Indication Innovator Patent Expiry Date(The U.S) Remdesivir Antiviruls(Ebola, Covid-19) Gilead -
Pomalidomide
API’s Name Indication Innovator Patent Expiry Date(The U.S) Pomalidomide Oncology drug Celgene -
Nirmatrelvir
API’s Name Indication Innovator Patent Expiry Date(The U.S) Nirmatrelvir 3C-Like Protease (3CLPRO) Inhibitor And SARS-Cov-2 Mpro Inhibitor -
Eltrombopag
API’s Name Indication Innovator Patent Expiry Date(The U.S) Eltrombopag ITP & Aplastic anemia Novartis & GSK May. 20, 2023 -
Ruxolitinib
API’s Name Indication Innovator Patent Expiry Date(The U.S) Ruxolitinib Myelofibrosis Novartis Jul. 6, 2024 -
Crisaborole
API’s Name Indication Innovator Patent Expiry Date(The U.S) Crisaborole Atopic Dermatitis and Eczema Pfizer Jun. 11, 2026